Pharmacologic options for the treatment of cachexia

Nutrition in Clinical Practice

Volumn 12, Issue 3, 1997, Pages 101-113

  Herrington, Annie M ^a   Herrington, Jon D ^a   Church, Charlene A ^a  

^a TEXAS A AND M HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0003474624     PISSN: 08845336     EISSN: 19412452     Source Type: Journal    
DOI: 10.1177/088453369701200302     Document Type: Article

References (85)

1. Bruera E. Is the pharmacological treatment of cancer cachexia possible? Support Care Cancer 1993;1:298-304.
2. Aisner J, Parnes H, Tait Net al.Appetite stimulation and weight gain with megestrol acetate. Semin Oncol 1990;17 (Suppl 9):2-7.
3. Bruera E. Clinical Management of anorexia and cachexia in patients with advanced cancer. Oncology 1992;49 (Suppl 2):35-42.
4. Schmoll E. Risks and benefits of various therapies for cancer anorexia. Oncology 1992;49 (Suppl 2):43-5.
5. Loprinzi CL, Ellison NM, Goldberg RMet al.Alleviation of cancer anorexia and cachexia: Studies of the Mayo clinic and the north central treatment group. Semin Oncol 1990;17 (Suppl 9):8-12.
6. Cangiano C, Laviano A, Muscaritili Met al.Cancer anorexia: New pathogenic and therapeutic insights. Nutrition 1996;12:S48-51.
7. DeWys WD. Management of cancer cachexia. Semin Oncol 1985;12:452-60.
8. Nahlen BL, Chu SY, Nwanyan OCet al.HIV wasting syndrome in the United States. AIDS 1993;7:183-8.
9. Macallan DC, Noble C, Baldwin Cet al.Energy expenditure and wasting in human immunodeficiency virus infection. N Engl J Med 1995;333:83-8.
10. Centers For Disease Control. Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. MMWR 1987;36 (Suppl 2S):3S-15S.
11. Von Roenn JH, Roth El, Craig R. HIV-related cachexia: potential mechanisms and treatment. Oncology 1992;49 (Suppl 2):50-4.
12. Grunfeld C, Pang M, Shimizu Let al.Resting energy expenditure caloric intake, and short-term weight change in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. Am J Clin Nutri 1992; 55:455-60.
13. Shils ME. Principles of nutritional support. Cancer 1979;43:2093-102.
14. Lieberman SA, Butterfield GE, Harrison Det al.Anabolic effects of recombinant insulin-like growth factor-I in cachectic patients with the acquired immunodeficiency syndrome. J Clin Endocrinol Metab 1994;78:404-10.
15. DeWys WD, Begg C, Lavin PTet al.Prognostic effect of weight loss prior to chemotherapy in cancer patients. Am J Med 1980;69:491-7.
16. Koretz R. Parenteral nutrition: Is it oncologically logical?J Clin Oncol 1984;2:534-8.
17. Lipman TO. Clinical trials of nutritional support in cancer: Parenteral nutrition in patients receiving cancer chemotherapy. Hematol Oncol Clin North Am 1991;5:91-102.
18. Tchekmedyian NS. Treatment of anorexia with megestrol acetate. NCP 1993;8:115-8.
19. Toomey D, Redmond HP, Bouchier-Hayes D. Mechanisms mediating cancer cachexia. Cancer 1995;76:2418-26.
20. Todorov P, Cariuk P, McDevitt Tet al.Characterization of a cancer cachectic factor. Nature 1996;379:739-42.
21. Bruera E, Roca E, Cedaro Let al.Action of oral methylprednisolone in terminal cancer patients: A prospective randomized double-blind study. Cancer Treat Rep 1985;69:751-4.
22. Moertel CG, Schutt AJ, Reitemeier RJet al.Corticosteroid therapy of preterminal gastrointestinal cancer. Cancer 1974;33:1607-9.
23. Popiela T, Lucchi R, Giongo F. Methylprednisolone as palliative therapy for female terminal cancer patients. Eur J Cancer Clin Oncol 1989;25:1823-9.
24. Willox JC, Corr J, Shaw Jet al.Prednisolone as an appetite stimulant in patients with cancer.Br Med J 1984;288:27.
25. Chlebowski RT, Herrold J, Ali Iet al.Influence of nandrolone decanoate on weight loss in advanced lung cancer. Cancer 1986;58:183-6.
26. Lyden E, Cvetkovska E, Westin Tet al.Effects of nandrolone propionate on experimental tumors and cancer cachexia. Metabolism 1995;44:445-51.
27. Halmi KA, Eckert E, Falk JR. Cyproheptadine for anorexia nervosa. Lancet 1982;1:1357-8.
28. Goldberg SC, Casper RC, Eckert ED. Effects of cyproheptadine in anorexia nervosa. Psychopharmacol Bull 1980;16:29-30.
29. Kardinal CG, Loprinzi CL, Schaid DJet al.A controlled trial of cyproheptadine in cancer patients with anorexia and/or cachexia. Cancer 1990;65:2657-62.
30. Regelson W, Burler JR, Schulz Jet al.Delta-9-tetrahydrocannabinol as an effective antidepressant and appetite-stimulating agent in advanced cancer patients. In: Braude MC, Szara S, eds. The pharmacology of marihuana. New York: Raven Press, 1976;763-75.
31. Wadleigh R, Spaulding GM, Lumbersky Bet al.Dronabinol enhancement of appetite in cancer patients [Abstract 1280]. Proc Am Soc Clin Oncol 1990;9:331.
32. Nelson K, Walsh D, Deeter Pet al.A phase II study of delta-9-tetrahydrocannabinol for appetite stimulation in cancer-associated anorexia. J Palliat Care 1994;10:14-8.
33. Lelli G, Angelelli B, Giambiasi MEet al.The anabolic effect of high dose medroxyprogesterone acetate in oncology. Pharmacol Res Commun 1983;15:561-8.
34. Gregory EJ, Cohen SC, Oines DWet al.Megestrol acetate in the treatment of advanced post-menopausal breast cancer. Eur J Surg Oncol 1986;12:43-5.
35. Loprinzi CL, Schaid DJ, Dose AMet al.Body-composition changes in patients who gain weight while receiving megestrol acetate. J Clin Oncol 1993;11:152-4.
36. Megace product information. Bristol-Myers Oncology Division, Princeton, NJ, 1996.
37. Pairault J, Green H. A study of the adipose conversion of suspended 3T3 cells by using glycerophosphate dehydrogenase as differentiation marker. Proc Natl Acad Sci USA 1979;76:5138-42.
38. Feliu J, Gonzalez-Baron M, Berrocal A,et al.Usefulness of megestrol acetate in cancer cachexia and anorexia: A placebo-controlled study. Am J Clin Oncol 1992;15:436-40.
39. Bruera E, Macmillan K, Kuehn Net al.A controlled trial of megestrol acetate on appetite, caloric intake, nutritional status, and other symptoms in patients with advanced cancer. Cancer 1990;66:1279-82.
40. Loprinzi CL, Ellison NM, Schaid DJet al.Controlled trial of megestrol acetate for the treatment of cancer anorexia and cachexia. J Natl Cancer Inst 1990;82:1127-32.
41. Tchekmedyian NS, Hickman M, Siau Jet al.Megestrol acetate in cancer anorexia and weight loss. Cancer 1992;69:1268-74.
42. Loprinzi CL, Ellison NM, Schaid DJet al.Phase III evaluation of four doses of megestrol acetate as therapy for patients with cancer anorexia and or cachexia. J Clin Oncol 1993;11:762-7.
43. Gebbia V, Testa A, Gebbia N. Prospective randomised trial of two dose levels of megestrol acetate in the management of anorexia-cachexia syndrome in patients with metastatic cancer. Br J Cancer 1996;73:1576-80.
44. Azcona C, Castro L, Crespo Eet al.Megestrol acetate therapy for anorexia and weight loss in children with malignant solid tumors. Aliment Pharmacol Ther 1996;10:577-86.
45. Donnelly S, Walsh TD. Low-dose megestrol acetate for appetite stimulation in advanced cancer. J Pain Symptom Manage 1995;10:182-3.
46. Ackermann M, Kirchner H, Atzpodien J. Low-dose megestrol acetate can abrogate cachexia in advanced tumor patients receiving systemic interferon-α and or interleukin-2 based antineoplastic therapy. Anti-cancer Drugs 1993;4:585-7.
47. Goldberg RM, Loprinzi CL, Mailliard JAet al.Pentoxifylline for treatment of cancer anorexia and cachexia? A randomized, double-blind, placebo-controlled trial. J Clin Oncol 1995;13:2856-9.
48. Silverstein R, Bhatia P, Svoboda DJ. Effect of hydrazine sulfate on glucose-regulating enzymes in the normal and cancerous rat. Immunopharmacology 1989;17:37-53.
49. Gold J. Proposed treatment of cancer by inhibition of gluconeogenesis. Oncology 1968;22:185-207.
50. Kosty M, Fleishman S, Herndon Jet al.Cisplatin, vinblastine, and hydrazine sulfate (NSC 150014) in advanced non-small lung cancer (NSCLC): a randomized, placebo controlled, double-blind phase III study [Abstract 982]. Proc Am Soc Clin Oncol 1992;11:294.
51. Loprinzi CL, Kuross SA, O'Fallon JR,et al.Randomized placebo-controlled evaluation of hydrazine sulfate in patients with advanced colorectal cancer. J Clin Oncol 1994;12:1121-5.
52. Loprinzi CL, Goldberg RM, Su JQet al.Placebo-controlled trial of hydrazine sulfate in patients with newly diagnosed non-small cell lung cancer. J Clin Oncol 1994;12:1126-9.
53. Lissoni P, Paolorossi F, Tancini Get al.Is there a role for melatonin in the treatment of neoplastic cachexia?Eur J Cancer 1996;32A:1340-3.
54. Fearon KC, Falconer JS, Ross JAet al.An open-label phase I-II dose escalation study of the treatment of pancreatic cancer using lithium γ-linolenate. Anticancer Res 1996; 16:867-74.
55. Wigmore SJ, Ross JA, Falconer JSet al.The effect of polyunsaturated fatty acids on the progress of cachexia in patients with 1 pancreatic cancer. Nutrition 1996;12(1 Suppl):S27-30.
56. Lundholm K, Gelin J, Hyltander Aet al.Anti-inflammatory treatment may prolong survival in undernourished patients with meta-static solid tumors. Cancer Res 1994; S4(21):5602-6.
57. Macallan DC, Noble C, Baldwin Cet al.Energy expenditure and wasting in human immunodeficiency virus infection. N Engl J Med 1995;333:83-8.
58. Kotler DP, Grunfeld C. Pathophysiology and treatment of AIDS wasting syndrome AIDS clinical review, Volberding P, Jacobsen MA (eds), Marcel Dekker Inc., New York; 229-75, 1995.
59. Cat L, Coleman RL. Treatment for HIV wasting syndrome. Ann Pharmacother 1994;28:595-7.
60. Kotler DP, Wang J, Pierson R. Studies of body composition in patients with the acquired immunodeficiency syndrome. Am J Clin Nutr 1985;42:1255-65.
61. Hellerstein M, Kahn J, Mudie Het al.Current approach to the treatment of human immunodeficiency virus-associated weight loss: pathophysiologic considerations and emerging management strategies. Semin Oncol 1917;8 (Suppl 9):17-33.
62. Weinroth SE, Parenti DM, Simon GL. Wasting syndrome in AIDS: pathophysiologic mechanisms and therapeutic approaches. Infect Agents Dis 1995;4:76-94.
63. Landman D, Sarai A, Sathe SS. Use of pentoxifylline therapy for patients with AIDS-related wasting: pilot study. Clin Infect Dis 1994;18:97-9.
64. Schroeder D, Hart L, Lynch S. Treatment for HIV wasting syndrome; drug information analysis service. Ann Pharmacother 1994;28:595-7.
65. Beal JE, Olson R, Laubenstein Let al.Dronabinol as a treatment for anorexia associated with weight loss in patients with aids. J Pain Symptom Manage 1995;10:89-97.
66. Struwe M, Kaempfer SH, Geiger CJet al.Effect of dronabinol on nutritional status in HIV infection. Ann Pharmacother 1993;27:827-31.
67. Von Roenn J, Murphy R, Wegner N. Megestrol acetate for treatment of anorexia and cachexia associated with human immunodeficiency virus infection. Semin Oncol 1990;17 (Suppl 9):13-6.
68. Oster MH, Enders SR, Samuels SJet al.Megestrol acetate in patients with AIDS and cachexia. Ann Intern Med 1994; 121:400-8.
69. Von Roenn J, Armstrong D, Kolter DP. Megestrol acetate in patients with AIDS-related cachexia. Ann Intern Med 1994; 121:393-4.
70. Loprinzi C, Jensen M, Jiang Net al.Effect of megestrol acetate on the human pituitary-adrenal axis. Mayo Clin Proc 1992;67:1160-2.
71. Engelsonet al.Effects of megestrol acetate therapy on body composition and circulating testosterone concentrations in patients with AIDS. AIDS 1995;9:1107-8.
72. McCloskey WW, Stofko JP. Human growth hormone therapy: an overview. Infusion 1996;February:40-4.
73. Krentz AJ, Koster FT, Crist DMet al.Anthropometric, metabolic, and immunological effects of recombinant human growth hormone in AIDS and AIDS-related complex. J AIDS 1993;6:245-51.
74. Schambelan M, Mulligan K, Grunfeld Cet al.Recombinant human growth hormone in patients with HIV-associated wasting. Ann Intern Med 1996;125:873-82.
75. Tai V, Schambelan M, Mulligan K. Abstract presented at the 11th International Conference on AIDS, 1996, Vancouver, British Columbia, Canada.
76. Lieberman SA, Butterfield GE, Harrison Det al.Anabolic effects of recombinant insulin-like growth factor-1 in cachectic patients with the acquired immunodeficiency syndrome. J Clin Endocrinol Metab 1994;78:404-10.
77. Waters D, Danska J, Hardy Ket al.Recombinant human group hormone, insulin-like growth factor 1, and combination therapy in AIDS-associated wasting. Ann Intern Med 1996;125:865-72.
78. Grinspoon S, Corcoran C, Lee Ket al.Loss of lean body and muscle mass correlates with androgen levels in hypogonadal men with acquired immunodeficiency syndrome and wasting. J Clin Endocrinol Metab 1996;81:40S1-8.
79. Sellmeyer DE, Grunfeld C. Tide Endocrine and metabolic disturbances in human immunodeficiency virus infection and the acquired immune deficiency syndrome. [Review] Endocr Rev 1996;17(5):518-32.
80. Berger JR, Pall L, Simpson Det al.Oxandrolone in AIDS wasting myopathy. J Neuro-Virol 1996;2:32.
81. Berger JR, Pall L, Winfield D. Effect of anabolic steroids on HIV-related wasting myopathy. South Med J 1993;86:865-6.
82. Reyes-Teran G, Sierra-Madero JG, Delcerro VM,et al.Effects of thalidomide HIV-associated on wasting syndrome. A randomized, double-blind, placebo controlled clinical trial. Int Conf AIDS 1994 Aug; 10:65 [Abstract 536B].
83. Klausner JD, Makonkawkeyoon S, Akarasewi Pet al.The effect of thalidomide on the pathogenesis of human immunodeficiency virus type 1 and m-tuberculosis infection. J Acquir Immun Def Syndro 1996;11:247-57.
84. Langreth R. FDA allows Celgene to widen access for thalidomide test for AIDS therapy. Wall Street Journal 1995;Aug 29.
85. Dezube BJ, Pardee AB, Chapman Bet al.Pentoxifylline decreases tumor necrosis factor expression and serum triglycerides in people with AIDS. NIAID AIDS Clinical Trials Group. J Acquir Immun Def Syndro 1993;6(7):787-94.